Atriva Therapeutics GmbH

www.atriva-therapeutics.com

Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body’s immune response to RNA viruses. Atriva Therapeutics was founded in 2015 in Tübingen by a team of leading scientists in viral research and seasoned industry experts and is based in Tübingen, Frankfurt, and Martinsried (IZB, near Munich), Germany. Atriva is a founding member of the BEAT-COV initiative. www.beat-cov.de For further information, please visit www.atriva-therapeutics.com and follow us on LinkedIn and Twitter (@AtrivaTx).

Read more

Reach decision makers at Atriva Therapeutics GmbH

Lusha Magic

Free credit every month!

Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body’s immune response to RNA viruses. Atriva Therapeutics was founded in 2015 in Tübingen by a team of leading scientists in viral research and seasoned industry experts and is based in Tübingen, Frankfurt, and Martinsried (IZB, near Munich), Germany. Atriva is a founding member of the BEAT-COV initiative. www.beat-cov.de For further information, please visit www.atriva-therapeutics.com and follow us on LinkedIn and Twitter (@AtrivaTx).

Read more
icon

Country

icon

City (Headquarters)

Tübingen

icon

Employees

1-10

icon

Founded

2015

icon

Estimated Revenue

$1 to $1,000,000

icon

Social

  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Vice President Clinical Development and Regulatory Affairs

    Email ****** @****.com
    Phone (***) ****-****
  • President and Chief Executive Officer Atriva Therapeutics Gmbh

    Email ****** @****.com
    Phone (***) ****-****
  • Chief Executive Officer

    Email ****** @****.com
    Phone (***) ****-****
  • Chief Medical Officer

    Email ****** @****.com
    Phone (***) ****-****

Technologies

(12)

Reach decision makers at Atriva Therapeutics GmbH

Free credits every month!

My account

Sign up now to uncover all the contact details